Answers are grounded in this paper and cite their sources.
Economic model reveals anti-Müllerian hormone screening reduces fertility treatment costs and delays in reproductive-aged women, highlighting improved healthcare efficiency.
Aim: Assess the budget impact of nationwide screening for diminished ovarian reserve (OR), via anti-Müllerian hormone (AMH) levels, to the Portugal National Health System (NHS). Patients & methods: The clinical journey was determined using literature and the family planning decision-making process/response using survey results. A panel of four local clinicians validated all assumptions/inputs. Results: Screening for OR led to an expected savings of € 9.4 million for the NHS, driven by a 24% reduction in medically assisted reproduction (MAR) use. When needed, referral for MAR was earlier and more women used first-line versus second-line techniques. The model estimated a 12% decrease in failure. Conclusion: This model shows AMH screening may allow more informed decisions, leading to a shorter fertility journey, more efficient use of treatments, and substantial cost-savings for the NHS.
No takes yet. Share an insight, caveat, or question.
Xavier et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: